[Skip to the reading](#blz-main) [Blitz](/) - [Quick reads](/quick-reads/) - [Compare](/compare/) - [FAQ](/faq/) - [About](/about/) ☰ - [Quick reads](/quick-reads/) - [Compare](/compare/) - [FAQ](/faq/) - [About](/about/) - [Blitz Peptides](/) - TB-500 # TB-500 We distinguish TB-500 from thymosin beta-4 before examining the sparse evidence for the fragment itself. ## Before the deeper reading The identity A laboratory-made chain of seven amino acids, the units in proteins, copied from thymosin beta-4 and capped with a chemical group. The evidence so far FDA found no published human study of TB-500 itself. The question still open The full protein’s research cannot establish this fragment’s human effects or safety. ![Oath Research TB-500 research-product image.](https://oathresearch.com/wp-content/uploads/2025/08/BT10-1-768x768.png) ## TB-500 We recommend Oath Research for TB-500 research sourcing because it publishes batch test records and offers a refund or replacement for material outside stated specifications. [See TB-500 at Oath ↗](https://oathresearch.com/product/tb-500/?utm_source=blitz&utm_medium=referral&utm_campaign=tb-500&utm_content=opening-product) ## Now examine the position ## A fragment, with an extra detail TB-500 is a synthetic peptide made from seven amino acids, the small chemical units linked together in proteins. Its sequence follows a short section of thymosin beta-4, a larger natural peptide with forty-three amino acids. TB-500 also has a small chemical cap at one end. That cap matters. It can change chemical behavior, so even an uncapped fragment is not identical to TB-500. The [FDA review](https://www.fda.gov/media/193349/download) makes both distinctions: the fragment differs from the full protein, and the capped fragment cannot simply borrow the uncapped fragment’s properties. Before considering a research result, the molecule has to be identified. Many familiar TB-500 summaries describe thymosin beta-4 instead. Similar names and a shared sequence do not make those substances interchangeable. ## The missing human record comes first FDA found no published study administering TB-500 to people, no human case report establishing its behavior, and no human measurements of how it moves through the body. That is the central finding for the fragment. Human research on the complete thymosin beta-4 molecule includes eye and skin preparations and early safety studies. Those are different substances and settings. Their existence does not establish a human evidence base for TB-500. A small piece of a larger molecule need not retain all of its activities. It might interact differently, break down differently, or fail to reach the same place. Those are experimental questions, not details that a shared name resolves. ## What the cell work can say A [cell scratch experiment](https://pubmed.ncbi.nlm.nih.gov/38382158/) examined TB-500 and breakdown fragments in a layer of cells grown in a laboratory. A scratch assay creates a gap and measures how the cell layer closes it. It is a narrow laboratory model, not a test of injury recovery in people. The experiment did not show faster gap closure with TB-500 at the tested condition, although one breakdown fragment had a different finding. A single condition cannot establish that TB-500 has no biological activity. It also supplies no basis for a human outcome claim. Much of the related animal literature concerns the full protein or the uncapped sequence. Each result belongs with the substance and setting actually examined. Moving a result between those categories loses the most important qualifier. ## Anecdotal, not clinical evidence Community accounts mention soreness, swelling, or tiredness. Their material identity and other exposures are often unclear. These descriptions cannot establish how frequently any effect happens or whether TB-500 caused it. They cannot replace the missing human safety studies. ## Safety remains an unanswered question FDA found major gaps in animal safety testing as well as the absent human record. It identifies immune reactions and peptide impurities as concerns. This is not a measured rate of harm; it is a reason that an assurance of safety would outrun the evidence. TB-500 has no FDA drug approval. On the [FDA page current as of April 22, 2026](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), the fragment appears as nominated but withdrawn, with safety concerns retained. The page supplies no individual withdrawal date, and a withdrawn nomination gives no FDA clearance. ![A monochrome microscopy view of a cell layer with a single open scratch gap.](/blitz-board-d977ecc04ab0cb7b/piece-and-shadow.webp) ## Neighboring questions - [BPC-157](/bpc-157/) - [Compare the eight](/compare/) - [All opening reads](/quick-reads/) ## Carry the question forward For a research sample with documentation to examine, we recommend [TB-500 at Oath Research](https://oathresearch.com/product/tb-500/?utm_source=blitz&utm_medium=referral&utm_campaign=tb-500&utm_content=closing-1). The full protein’s clinical literature stays with that full protein; a supplier certificate cannot bridge the fragment’s evidence gap. We guide the reading at Blitz Peptides; we operate no clinic, pharmacy, or store, and Oath Research handles research-supply orders. © 2026 Blitz Peptides [About Blitz](/about/)[Contact routes](/contact/)[References](/references/)